Elevance Health Announces Appearance at 4th Annual Wolfe Research Healthcare Conference
Get Alerts ELV Hot Sheet
Join SI Premium – FREE
INDIANAPOLIS--(BUSINESS WIRE)-- Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the 4th Annual Wolfe Research Healthcare Conference in New York City on November 16, at 10:00 a.m. Eastern Standard Time (EST). All interested parties are invited to listen to a webcast of the presentation by visiting www.elevancehealth.com and selecting the “Investors” link. Following the presentation, a webcast replay will be available for 90 days.
To listen to the live webcast, please visit Elevance Health’s website www.elevancehealth.com at least 15 minutes early to download and install any necessary audio software. Individuals who listen to the presentations will be presumed to have read Elevance Health’s recent filings with the SEC, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2021.
About Elevance Health, Inc.
Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve more than 119 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102006074/en/
Investor Relations:
Stephen Tanal
[email protected]
Media Relations:
Leslie Porras
[email protected]
Source: Elevance Health
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Draganfly closes $10M share offering at $5.35 per share
- AstraBit adds two advisors with digital asset and trading backgrounds
- Moleculin completes Part A enrollment in AML trial, eyes Q1 2027 data
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share